Ae21-Epigenetics in Aging and Cancer (Emerging)
Oncology / IBS-Ae21 / Emerging
We study the role of epigenetic heterogeneity in cancer and stem cell biology.
Research lines
- Dissection of the molecular bases of epigenetic memory.
- Analysis of epigenetic pathways associated with aging.
- Design of therapeutic interventions with drugs that slow down or reverse aging.
- Dissection of the epigenetic pathways that regulate metastatic dissemination.
- Design of therapeutic interventions with epigenetic drugs in cancer.
Keywords
chromatin, cancer, circadian rhythm, genomics, epigenetics, transcriptomics, stem cell, liquid biopsy, prenatal diagnosis
JOAN DOMINGO REINES
Isabel Maria Garcia Cabrera
SERGIO SERRANO CORRAL
Adrian Castle Linde
JIAJUN XIE
ANDREA SERRANO PRADOS
IVAN FERNANDEZ RENGEL
Mencia Espinosa Martinez
MARIA ALCAZAR FABRA
EFRES BELMONTE RECHE
LOURDES LOPEZ ONIEVA
LOVER GALLARDO DE LOS REYES
DAVID LANDEIRA FRIAS
MARIA JOSE MOYANO RODRIGUEZ
The molecular basis of cell memory in mammals: The epigenetic cycle
SCIENCE ADVANCES, 2024;
FI: 11,7; D1
COQ4 is required for the oxidative decarboxylation of the C1 carbon of coenzyme Q in eukaryotic cells
MOLECULAR CELL, 2024;
FI: 14,5; D1
The Role of SOX2 and SOX9 in Radioresistance and Tumor Recurrence
CANCER, 2024;
FI: 4,5; Q1
DNA G-quadruplexes in the genome of Trypanosoma cruzi as potential therapeutic targets for Chagas disease: Dithienylethene ligands as effective antiparasitic agents
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024;
FI: 6; Q1
EZH2 represses mesenchymal genes and upholds the epithelial state of breast carcinoma cells
CELL DEATH & DISEASE, 2024;
FI: 8,1; Q1
Changes in PRC1 activity during interphase modulate lineage transition in pluripotent cells
NATURE COMMUNICATIONS, 2023;
FI: 16,6; D1
The pediatric leukemia oncoprotein NUP98-KDM5A induces genomic instability that may facilitate malignant transformation
CELL DEATH & DISEASE, 2023;
FI: 9; Q1
EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumor colonization.
ONCOGENE, 2022;
FI: 8,756; D1
G-Quadruplex DNA as a Target in Pathogenic Bacteria: Efficacy of an Extended Naphthalene Diimide Ligand and Its Mode of Action
JOURNAL OF MEDICINAL CHEMISTRY, 2022;
FI: 8,039; D1
Thiosugar naphthalene diimide conjugates: G-quadruplex ligands with antiparasitic and anticancer activity
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022;
FI: 7,088; D1
Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics
PHARMACEUTICS, 2022;
FI: 6,525; Q1
Bioimaging of Lysosomes with a BODIPY pH-Dependent Fluorescent Probe
MOLECULES, 2022;
FI: 4,927; Q2
Orphan CpG islands amplify poised enhancer regulatory activity and determine target gene responsiveness
NATURE GENETICS, 2021;
FI: 38,33; D1
Improved Functionality of Integration-Deficient Lentiviral Vectors (IDLVs) by the Inclusion of IS2 Protein Docks..
PHARMACEUTICS, 2021;
FI: 6,321; Q1
ADAMTS1 Supports Endothelial Plasticity of Glioblastoma Cells with Relevance for Glioma Progression
BIOMOLECULES, 2021;
FI: 4,879; Q2
Polycomb regulation is coupled to cell cycle transition in pluripotent stem cells
SCIENCE ADVANCES, 2020;
FI: 13,117; D1
The Polemic Diagnostic Role of TP53 Mutations in Liquid Biopsies from Breast, Colon and Lung Cancers
CANCER, 2020;
FI: 6,126; Q1
The molecular clock protein Bmal1 regulates cell differentiation in mouse embryonic stem cells
LIFE SCIENCE ALLIANCE, 2020;
FI: 2,622; Q2
NOMePlot: analysis of DNA methylation and nucleosome occupancy at the single molecule
SCIENTIFIC REPORTS, 2019;
FI: 4,011; Q1
Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents
CELLS, 2019;
FI: 5,656; Q1
GnRH agonist treatment of luteal phase deficiency in HCG-triggered IVF cycles: a matched case-control study
REPRODUCTIVE BIOMEDICINE ONLINE, 2019;
FI: 2,93; Q1
Perioperative outcome of lung cancer surgery in women: results from a Spanish nationwide prospective cohort study
JOURNAL OF THORACIC DISEASE, 2019;
FI: 2,027; Q3
Mitotic labeling by the Polycomb epigenetic repressor system in embryonic stem cells: Determining genomic binding of Polycomb complexes and their associated histone modifications during mitosis by ChIP-seq.
Funder: UNIVERSITY OF GRANADA
File number: PPJIA2023.038
Execution time: 01/01/2024 - 31/12/2024
IP: MARIA ALCAZAR FABRA
Development of new therapeutic approaches for the treatment of multiple myeloma
Funder: UNIVERSITY OF GRANADA
File number: C-CTS-274-UGR23
Execution time: 01/01/2024 - 31/12/2026
IP: LOURDES LOPEZ ONIEVA
Study of transcriptional memory in pluripotent stem cells
Funder: UNIVERSITY OF GRANADA
File number: A-CTS-264-UGR23
Execution time: 01/01/2024 - 31/12/2026
IP: EFRES BELMONTE RECHE
Dissecting the epigenetic cycle in stem cells
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: IHRC22/00007
Execution time: 01/01/2023 - 31/12/2026
PI: DAVID LANDEIRA FRIAS
AID AIMED FOR ATTRACTING RESEARCH TALENT (EMERGIA PROGRAM)
Funder: DEPARTMENT OF UNIVERSITY, RESEARCH AND INNOVATION
File number: EMC21_00253
Execution time: 01/01/2023 - 31/12/2026
Role of Polycomb proteins as regulators of differentiation during the cell cycle of pluripotent cells
Funder: UNIVERSITY OF GRANADA
File number: A-BIO-6-UGR20
Execution time: 01/07/2021 - 30/06/2023
Mitotic Bookmarking By Polycomb Proteins In Stem Cell
Funder: COUNCIL OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE AND UNIVERSITIES
File number: PY20_0068
Execution time: 04/10/2021 - 30/06/2023
PI: DAVID LANDEIRA FRIAS
POLYCOMB RECRUITMENT DURING CELL CYCLE TRANSITION
Funder: STATE RESEARCH AGENCY
File number: EUR2021-122005
Execution time: 01/12/2021 - 01/12/2023
PI: DAVID LANDEIRA FRIAS
A retrospective observational study was conducted to describe the clinical characteristics, management, and outcomes of the anti-GPRC5D bispecific antibody (TALquetamab) in patients with relapsed-refractory multiple myeloma treated outside of a clinical trial (SPR/NPP) in Spain. The BiTAL study
Financier: EVIDENZE HEALTH ESPAÑA, SLU
Test type: OBSERVATIONAL STUDY WITH MEDICINES
Execution time: 16/08/24 - 30/09/25
IP: ISABEL MARIA GARCIA CABRERA